A clinical trial involving a group of AIA clients with pre-diabetic and type 2 diabetes has helped improve their health outcomes, says the firm.
Len Elikhis, the company’s Chief Product and Investments Officer, says the 12-week trial – developed by Prekure – found all of those who shared their data achieved reduced blood sugar levels. Half achieved a clinically significant reduction in their blood sugar levels.
AIA says 49 clients were enrolled in the programme of which 74% (36) completed the programme.
As a result of the pilot, AIA NZ is working with Prekure to explore options to introduce the programme into its service offering.
Grant Schofield, Prekure Chief Science Officer, says around one in 20 New Zealanders have been diagnosed with type 2 diabetes.
“By 2040, this is projected to almost double to one in 10,” he says.
Those taking part in the trial were encouraged to change their diet, and take part in health coaching sessions.
“Seeing all participants report a reduced blood sugar level, which is a key diabetes indicator, compared to when they started the trial was incredible,” says Schofield.